This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Amgen (AMGN) to Boost Inflammation Pipeline With Rodeo Buyout
by Zacks Equity Research
Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.
BMYPositive Net Change AMGNPositive Net Change RGENPositive Net Change NBRVPositive Net Change
biotechs
Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More
by Zacks Equity Research
The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.
INCYPositive Net Change GSKPositive Net Change BMYPositive Net Change VRTXPositive Net Change VIRPositive Net Change KLDOPositive Net Change
biotechs
7 Best Leveraged/Inverse ETFs Up 20% Plus in March
by Sweta Killa
Amid the bull and bear tug-of-war, the demand for leveraged and inverse-leveraged ETFs has increased.
RETLNo Net Change LABDPositive Net Change NAILNegative Net Change TPORNegative Net Change DUSLPositive Net Change UTSLPositive Net Change
biotechs cloud-computing construction etfs industrial-products retail transportation utilities
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
PFEPositive Net Change MRNAPositive Net Change IBBNegative Net Change BBHPositive Net Change BTECPositive Net Change
biotechs etfs
bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.
GILDNegative Net Change NVSPositive Net Change BMYPositive Net Change
biotechs
Roche's (RHHBY) SMA Treatment Evrysdi Secures EC Approval
by Zacks Equity Research
Roche (RHHBY) gains a regulatory nod for its SMA treatment Evrysdi in Europe for patients aged two months and above.
BIIBPositive Net Change RHHBYPositive Net Change NVSPositive Net Change PTCTPositive Net Change
biotechs pharmaceuticals
Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre
by Zacks Equity Research
The European Commission approves Incyte's (INCY) Pemazyre (pemigatinib) for the treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
INCYPositive Net Change RGENPositive Net Change NBRVPositive Net Change CTMXNegative Net Change
biotechs
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
AZNPositive Net Change MRNAPositive Net Change NVAXPositive Net Change IBBNegative Net Change XBINegative Net Change PPHPositive Net Change BBHPositive Net Change
biotechs etfs
Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.
MYGNNegative Net Change QGENPositive Net Change LHNegative Net Change EXASPositive Net Change
biotechs medical
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance
by Zacks Equity Research
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
RHHBYPositive Net Change MRKNegative Net Change SGENPositive Net Change GMABPositive Net Change
biotechs
Gilead's (GILD) Breast Cancer Drug MAA Validated by EMA
by Zacks Equity Research
Gilead's (GILD) regulatory application for breast cancer drug has been validated by the regulatory body in Europe.
AZNPositive Net Change RHHBYPositive Net Change GILDNegative Net Change MRKNegative Net Change
biotechs
Warp Speed Innovation: How the Pandemic Ignited Biotech
by Kevin Cook
As the scientific community circled their wagons to fight this pandemic, new innovations were brought to the forefront and put into use at breakneck speed. Kevin Cook can help you find the most promising biotech opportunities.
AZNPositive Net Change RHHBYPositive Net Change GILDNegative Net Change MRKNegative Net Change
biotechs earnings
Bristol-Myers (BMY) Announces Results From Opdivo Combo Study
by Zacks Equity Research
Bristol-Myers (BMY) announces encouraging primary results from a study, evaluating a fixed-dose combination of relatlimab and immuno-oncology drug, Opdivo, in metastatic or unresectable melanoma.
RHHBYPositive Net Change MRKNegative Net Change MRNAPositive Net Change BMYPositive Net Change
biotechs
Moving Average Crossover Alert: Provention Bio (PRVB)
by Zacks Equity Research
Provention Bio (PRVB) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
PRVBPositive Net Change
biotechs medical
Kaleido (KLDO) Reports Positive Results from COVID-19 Study
by Zacks Equity Research
Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.
REGNPositive Net Change GSKPositive Net Change VIRPositive Net Change KLDOPositive Net Change
biotechs pharmaceuticals
AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine
by Zacks Equity Research
AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.
JNJPositive Net Change AZNPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs pharmaceuticals
Oncolytics Biotech (ONCY) Enters Overbought Territory
by Zacks Equity Research
Oncolytics Biotech (ONCY) has moved higher as of late, but there could definitely be trouble on the horizon for this company
ONCYNegative Net Change
biotechs medical
Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive
by Zacks Equity Research
Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.
PFEPositive Net Change RGENPositive Net Change NBRVPositive Net Change MYOVPositive Net Change
biotechs
Biotech Stock Roundup: REGN Cocktail Data Positive, INCY's Jakafi Disappoints & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Regeneron (REGN) and Incyte (INCY).
REGNPositive Net Change RHHBYPositive Net Change INCYPositive Net Change IONSNegative Net Change ZEALPositive Net Change CVACNegative Net Change
biotechs pharmaceuticals
Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive data from a phase III study on its antibody cocktail for COVID-19.
REGNPositive Net Change RHHBYPositive Net Change GSKPositive Net Change VIRPositive Net Change
biotechs pharmaceuticals
5 Megatrends of Medicine: Profiting from Breakthrough Science
by Kevin Cook
We're still in the early years of "The Century of Biology". Kevin can help you get involved with this innovative space that will soon cross $800 billion in revenues.
REGNPositive Net Change RHHBYPositive Net Change GSKPositive Net Change VIRPositive Net Change
biotechs earnings medical pharmaceuticals
Zacks.com featured highlights include: UFP Industries, Interactive Brokers Group, Avid Bioservices, Amtech Systems and Gaia
by Zacks Equity Research
Zacks.com featured highlights include: UFP Industries, Interactive Brokers Group, Avid Bioservices, Amtech Systems and Gaia
IBKRNegative Net Change UFPIPositive Net Change GAIANegative Net Change CDMOPositive Net Change
biotechs industrial-products tech-stocks
Roche's (RHHBY) Tecentriq Meets Primary Goal in Lung Cancer Study
by Zacks Equity Research
Roche's (RHHBY) Tecentriq meets primary endpoint of disease-free survival at the interim analysis in lung cancer patients.
AZNPositive Net Change RHHBYPositive Net Change MRKNegative Net Change BMYPositive Net Change
biotechs pharmaceuticals
Do Options Traders Know Something About Frequency Therapeutics (FREQ) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Frequency Therapeutics (FREQ) stock based on the movements in the options market lately.
biotechs medical
Healthpeak (PEAK) Announces Two Life-Science Developments
by Zacks Equity Research
Healthpeak's (PEAK) ground-up development of Nexus on Grand in South San Francisco and Callan Ridge campus in San Diego is in line with its strategy to expand life-science assets in key markets.
EXRNegative Net Change GNLPositive Net Change PINEPositive Net Change
biotechs reit